Literature DB >> 12758240

In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.

Pierre Mahy1, Marc De Bast, Bernard Gallez, John Gueulette, Cameron J Koch, Pierre Scalliet, Vincent Grégoire.   

Abstract

BACKGROUND AND
PURPOSE: The primary objective of this study was to establish in vivo the relationship between 2-2-nitro-1H-imidazol-1yl-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) adduct formation and intratumoral oxygen concentrations measured by electron paramagnetic resonance (EPR) in a tumor model mimicking a clinical situation. The secondary objective was an attempt to calibrate in situ the immunofluorescence (IF) signal with EPR oximetry.
MATERIALS AND METHODS: IM syngeneic fibrosarcoma (NFSA) bearing C3H mice were used. Three days after injection of a paramagnetic charcoal into the tumor, the mice were anesthetized, injected with the hypoxic marker EF5, and monitored every 20 min for 3 h with a low-frequency EPR spectrometer. Animals were allowed to breath either under 21 or 100% O(2). Tumors were then harvested, frozen, cut into sections including the charcoal and processed for EF5 adducts detection using monoclonal antibodies. Slices were viewed with a fluorescence microscope and 190x140 micrometer areas surrounding the charcoal were digitized and analyzed with the NIH-Image and Adobe Photoshop software. The fluorescence intensity (FI) was measured in the whole pictures and in strips of 10 micrometer around the charcoal.
RESULTS: EF5 binding increased with decreasing pO(2), most substantially at pO(2) below 5 mm Hg. Baseline (ambient air) pO(2) reached 3.2+/-2.1 mm Hg in NFSA tumors. It increased to 9.8+/-3.2 mm Hg under 100% O(2). A statistically significant correlation was observed on an individual tumor basis between the FI in the first 10 micrometer strip around the charcoal and the pO(2) determined by EPR oximetry (Wilcoxon signed rank test: P<0.001).
CONCLUSIONS: The present study confirms the intrinsic relationship between EF5 adduct binding and intratumoral pO(2) in an in vivo environment under biologically-relevant pO(2) values of less than 10 mm Hg.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12758240     DOI: 10.1016/s0167-8140(03)00028-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma.

Authors:  Takaaki Beppu; Kazunori Terasaki; Toshiaki Sasaki; Shunrou Fujiwara; Hideki Matsuura; Kuniaki Ogasawara; Koichiro Sera; Noriyuki Yamada; Noriyuki Uesugi; Tamotsu Sugai; Kohsuke Kudo; Makoto Sasaki; Shigeru Ehara; Ren Iwata; Yoshihiro Takai
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

2.  Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts.

Authors:  Brennan J Wadsworth; Che-Min Lee; Kevin L Bennewith
Journal:  Br J Cancer       Date:  2022-01-14       Impact factor: 9.075

Review 3.  Clinical EPR: unique opportunities and some challenges.

Authors:  Harold M Swartz; Benjamin B Williams; Bassem I Zaki; Alan C Hartford; Lesley A Jarvis; Eunice Y Chen; Richard J Comi; Marc S Ernstoff; Huagang Hou; Nadeem Khan; Steven G Swarts; Ann B Flood; Periannan Kuppusamy
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

4.  A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

Authors:  Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

5.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

Review 6.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

7.  Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.

Authors:  P Mahy; M De Bast; J Gillart; D Labar; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-08       Impact factor: 9.236

Review 8.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

9.  Over-Generalizing About GC (Hypoxia): Pitfalls of Limiting Breadth of Experimental Systems and Analyses in Framing Informatics Conclusions.

Authors:  Mark R Boothby; Ariel Raybuck; Sung Hoon Cho; Kristy R Stengel; Volker H Haase; Scott Hiebert; Jingxin Li
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.